Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
You must be a Standard 1 Year member to access this content.
Goodwin advised Pathology Watch on the sale to Sonic Healthcare. Sonic Healthcare acquired Utah-based medical-tech provider Pathology Watch for US$150 million in what the Australian company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as US counsel to Talon Cyber Security in the definitive agreement to be acquired by Palo Alto Network. Palo Alto Networks has acquired...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Biotheus Inc. on the agreement with BioNTech. Biotheus Inc. announced an exclusive global license and collaboration agreement with BioNTech. BioNTech will be developing, manufacturing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Advanced Biologics in its merger with Isto Biologics. Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous...
You must be a Standard 1 Year member to access this content.
Banco J.P. Morgan S.A. is acting as exclusive financial advisor, Goodwin LLP as exclusive legal advisor, and PWC as exclusive accounting and tax advisor to Acino....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Orionis Biosciences on the collaboration with Genentech. Privately held Orionis Biosciences announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover...
You must be a Standard 1 Year member to access this content.
Goodwin advised Seagen on the deal. Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that it has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc....
You must be a Standard 1 Year member to access this content.
Goodwin advised Alpha Wave Global on the investment. Alpha Wave Global, alongside Mubadala Capital, invested in Aman Group’s $360 million funding round. The investment values Aman, run...
You must be a Standard 1 Year member to access this content.
Goodwin advised bit.bio on the agreement. BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
